Welcome to Multibagg AI
Log in to access personalized features
IRIS
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Discovery themes featuring this stockBearish
4
Neutral
7
Bullish
3
Bearish
21
Neutral
7
Bullish
18
Bearish
17
Neutral
0
Bullish
15
Bearish
17
Neutral
0
Bullish
15
Bearish
17
Neutral
0
Bullish
15
Bearish
17
Neutral
0
Bullish
15
Discovery themes featuring this stock| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
122.90 | 1,327 Cr | 34.82 | 1.32 | 0.00 | 3.72 | 6.20 | 2.04 | ||
160.65 | 1,267 Cr | 75.66 | 5.02 | 0.00 | 6.14 | 8.20 | 5.62 | ||
135.95 | 1,116 Cr | 23.60 | 4.14 | 1.84 | 15.67 | 16.97 | 10.17 | ||
550.05 | 875 Cr | 33.86 | 6.29 | 0.00 | 18.77 | 27.73 | 17.88 | ||
228.50 | 486 Cr | 24.24 | 4.24 | 0.00 | 17.54 | 26.13 | 16.39 | ||
167.45 | 330 Cr | 18.50 | 3.23 | 0.00 | 17.47 | 17.02 | 8.62 | ||
110.30 | 250 Cr | 22.39 | 2.57 | 0.00 | 11.48 | 15.13 | 8.40 | ||
| Median: 7 Co. | — | 160.65 | 875 Cr | 24.24 | 4.14 | 0.00 | 15.67 | 16.97 | 8.62 |
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
GPT Healthcare Ltd (GPTHEALTH) is currently trading at 139.20 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
GPT Healthcare Limited operates a network of mid-sized multispecialty hospitals under the ILS Hospitals brand, delivering secondary, tertiary and emerging quaternary care across Eastern and Central India with a current system capacity stated at 719 beds and ongoing additions including a 155-bed Jamshedpur hospital due to commission in Q4 FY27. Q1 FY27 performance showed operational traction: revenue from operations of INR126.2 crores, EBITDA of INR26.2 crores (20.4% margin) and PAT of INR12.7 crores, with management reporting revenue growth of 18.2% and PAT improvement of 66% YoY, driven by stronger occupancy at mature hospitals and a favorable specialty mix. The company is strategically focused on higher-end tertiary and quaternary specialties—robotic surgeries (>800 cumulative procedures), renal transplants (>700 completed), oncology with PET and linear accelerator capacity—and has seen ARPOB improvements (network ARPOB ~INR42,350; Salt Lake INR45,300; Dumdum INR43,041). GPT Healthcare is scaling with an asset-light bias where feasible, expecting modest incremental project debt for Jamshedpur (~INR25 crores) while targeting FY27 EBITDA margin of ~21% and long‑term ROE/ROCE near 25%, signaling disciplined capital allocation and margin improvement as primary levers. The network is leveraging regional transnational patient flows (Bangladesh) and specialized clinical milestones such as liver transplants and robotic MAKO joint replacements to deepen market differentiation, though occupancy remains uneven while newer hospitals ramp towards break‑even timelines.
Over the past 52 weeks, GPT Healthcare Ltd has traded between a low of ₹114.00 and a high of ₹175.00. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
GPT Healthcare Ltd has a market capitalization of approximately 1,152.46. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
GPT Healthcare Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 24.38 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 1,152.46 Cr, GPT Healthcare Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
GPT Healthcare Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of GPT Healthcare Ltd is 24.38. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
GPT Healthcare reported Q1FY27 net profit after tax of ₹12.73 crore (₹1,273.14 lakh), up 65.9% year-on-year from ₹7.68 crore (₹768.18 lakh).
GPT Healthcare Limited operates a network of mid-sized multispecialty hospitals under the ILS Hospitals brand, delivering secondary, tertiary and emerging quaternary care across Eastern and Central India with a current system capacity stated at 719 beds and ongoing additions including a 155-bed Jamshedpur hospital due to commission in Q4 FY27.
Q1 FY27 performance showed operational traction: revenue from operations of INR126.2 crores, EBITDA of INR26.2 crores (20.4% margin) and PAT of INR12.7 crores, with management reporting revenue growth of 18.2% and PAT improvement of 66% YoY, driven by stronger occupancy at mature hospitals and a favorable specialty mix.
The company is strategically focused on higher-end tertiary and quaternary specialties—robotic surgeries (>800 cumulative procedures), renal transplants (>700 completed), oncology with PET and linear accelerator capacity—and has seen ARPOB improvements (network ARPOB ~INR42,350; Salt Lake INR45,300; Dumdum INR43,041).
GPT Healthcare is scaling with an asset-light bias where feasible, expecting modest incremental project debt for Jamshedpur (~INR25 crores) while targeting FY27 EBITDA margin of ~21% and long‑term ROE/ROCE near 25%, signaling disciplined capital allocation and margin improvement as primary levers.
The network is leveraging regional transnational patient flows (Bangladesh) and specialized clinical milestones such as liver transplants and robotic MAKO joint replacements to deepen market differentiation, though occupancy remains uneven while newer hospitals ramp towards break‑even timelines.
Healthcare Services
Hospital
1,152 Cr
Low Risk
24.4
60.9
0.8
4.3
175.00
114.00
Sales CAGR
Profit CAGR
ROE
ROCE
